Is Plasma protein fraction registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 6 valid registrations of Plasma protein fraction, including OCTAPLAS LG 45-70MG/ML (45-70 mg/ml, Solution for infusion, SAR 614.10); PENTAGLOBIN (50 mg/ml, Solution for infusion, SAR 2241.40); PENTAGLOBIN AMP I.V (50 mg/ml, Solution for infusion, SAR 224.15); PLASMA PROTEIN FRACTION 5% SOLUTION (5 %, Solution for injection, SAR 278.00); PLASMANATE 5% SOLUTION FOR I.V. INJECTION (5 %, Solution for injection, SAR 158.90).

Active substance

Plasma protein fraction

SFDA 8

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
OCTAPLAS LG 45-70MG/ML	45-70 mg/ml	Solution for infusion · Intravenous use	1 Bag	SAR 614.10	Biological · Prescription	OCTAPHARMA AG	Valid
PENTAGLOBIN	50 mg/ml	Solution for infusion · Intravenous use	1 Ampoule	SAR 2241.40	Biological · Prescription	BIOTEST	Valid
PENTAGLOBIN	50 mg/ml	Solution for infusion · Intravenous use	1 Ampoule	SAR 1120.70	Biological · Prescription	BIOTEST	Valid
PENTAGLOBIN AMP I.V	50 mg/ml	Solution for infusion · Intravenous use	1 Ampoule	SAR 224.15	Biological · Prescription	BIOTEST	Valid
PLASMA PROTEIN FRACTION 5% SOLUTION	5 %	Solution for injection · Intravenous use	1 Bottle	SAR 278.00	Biological · Prescription	OCTAPHARMA	Valid
PLASMANATE 5% SOLUTION FOR I.V. INJECTION	5 %	Solution for injection · Intravenous use	1 Ampoule	SAR 158.90	Biological · Prescription	GRIFOLS THERAPEUTICS INC	Valid
OCTAPLAS	9.0 - 14.0 g	Solution · Intravenous use	1 Bag	SAR 519.10	Biological · Prescription	OCTAPHARMA	Withdrawn by MAH · Not Marketed
PLASMA PROTEIN FRACTION 5% VIAL	5 %	Solution for injection · Intravenous use	1 Vial	SAR 247.90	Biological · Prescription	BIOTEST	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

DYSPEPSIA; HEMOPHILIA A, HEMOPHILIA B, VON WILLEBRAND DISEASE, ACQUIRED HEMOPHILIA; PEPTIC ULCER

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.